Hillsdale Investment Management Inc. Innoviva, Inc. Transaction History

Hillsdale Investment Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$14.56 - $16.78 $362,544 - $417,822	24,900 Added 8.57%	315,600 $4.81 Million
Q4 2023 Feb 09, 2024	BUY	$12.32 - $16.27 $3.58 Million - $4.73 Million	290,700 New	290,700 $4.66 Million
Q2 2021 Jul 29, 2021	SELL	$11.45 - $13.96 $1.96 Million - $2.39 Million	-171,300 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$9.33 - $12.48 $10,263 - $13,728	-1,100 Reduced 0.64%	171,300 $2.12 Million
Q2 2020 Aug 11, 2020	BUY	$11.49 - $15.26 $1.98 Million - $2.63 Million	172,400 New	172,400 $2.41 Million

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.23B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.